This retrospective study examined the epidemiology, costs, hospital admissions and length of stay (LOS), and mortality in cases classified as probable Dravet syndrome (DS) in the German healthcare system. This retrospective, insurance data analysis utilised the Vilua Healthcare research database, representing approximately 5% of the German population covered by statutory health insurance. Probable DS cases were defined by an algorithm using ICD-10 coding and AED prescriptions. Costs and LOS were stratified by the use of emergency seizure medication. The cost of illness was assessed on all hospital admissions between 1 January 2007 and 31 December 2016. Mortality was calculated and compared to age- and gender-matched database controls with an equal observation time. Based on 64 patients in 2016 with probable DS, the mean age was 33.2 years with a calculated standardised prevalence of 4.7/100,000 (Table 1). Patients with emergency drug use had a higher rate and LOS in hospital, as well as treatment costs, than those without. Inpatient care was the highest treatment cost (Table 2). Over 96 months, mortality was 13.14-fold higher in probable DS than the control group (Figure). The findings of this retrospective study indicate that patients with probable DS incur substantial costs related to hospitalisation, medication, outpatient services, and multidisciplinary care. Emergency medication can be used as a marker for disease severity resulting in considerably more hospitalisations and higher costs. The higher mortality rate in patients with DS reinforces the need for new patient treatment.